CytoSorbents Corporation (CTSO)

[orangecat]

When speaking of the FDA not accepting a surrogate end point for a Sepsis approval of Cytosorb through EAP Dr. Chan stated "Finally, in terms of other advantages of the EAP program, sepsis is already considered a
disease that would receive expedited review, so we should benefit from a kind of “fast-
track” when we get there."